Michael Howell Purchases 7,987 Shares of Zura Bio Limited (NASDAQ:ZURA) Stock

Zura Bio Limited (NASDAQ:ZURA) insider Michael Howell bought 7,987 shares of the business’s stock in a transaction on Monday, April 22nd. The stock was bought at an average cost of $3.13 per share, for a total transaction of $24,999.31. Following the purchase, the insider now directly owns 7,987 shares of the company’s stock, valued at approximately $24,999.31. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Zura Bio Stock Performance

ZURA opened at $4.41 on Friday. The company has a fifty day simple moving average of $3.19 and a 200 day simple moving average of $4.01. Zura Bio Limited has a 12 month low of $2.00 and a 12 month high of $14.00.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $16.00 price target (down from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $16.40.

Institutional Investors Weigh In On Zura Bio

Several large investors have recently modified their holdings of the business. Lynx1 Capital Management LP bought a new position in shares of Zura Bio during the 3rd quarter valued at about $65,000. Forefront Analytics LLC acquired a new position in shares of Zura Bio in the third quarter valued at approximately $95,000. Bank of New York Mellon Corp bought a new stake in shares of Zura Bio during the third quarter worth $224,000. Raymond James & Associates raised its holdings in shares of Zura Bio by 14.0% during the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after acquiring an additional 9,481 shares during the period. Finally, Eisler Capital US LLC bought a new stake in Zura Bio in the 3rd quarter valued at $660,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.